期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 35, 期 19, 页码 2117-+出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2016.71.6795
关键词
-
类别
资金
- EMD Serono
- Celldex
- ARMO BioSciences
- BioMed Valley Discoveries
- Novartis
- Janssen Oncology
- GlaxoSmithKline
- Immunocore
- Calithera Biosciences
- Phosplatin Therapeutics
- Genentech
- Roche
- Aileron Therapeutics
- AstraZeneca
- eFFECTOR Therapeutics
- MedImmune
- Pfizer
- Bristol-Myers Squibb
- TESARO
- Merck
- Millennium
- Synta
- Eli Lilly
- AbbVie
- Gilead Sciences
- Celgene
- Five Prime Therapeutics
- Bayer
- Boston Biomedical
- Plexxikon
- Array BioPharma
- Bristol Meyers
- Bavarian Nordic
- Medivation/Astellas
Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on >= 5% of tumor cells. Results Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0%), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%). Conclusion Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC. (C) 2017 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据